Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridinilazole vs Vancomycin in Clostridioides Difficile Infection
NCT03595553Phase 3Completed
- Sponsor
- Summit Therapeutics
- Start
- Jan 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of ridinilazole in Clostridioides difficile infection (CDI), sponsored by Summit Therapeutics. Started Jan 2019; status: completed.
02
Drugs
ridinilazole
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03595553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595553.